Evolution of Simulation and Digital Twin in Health Care: From Discovery to Design and Integration DOI
Yue Dong, Amos Lal, Alexander S. Niven

et al.

Simulation foundations, methods and applications, Journal Year: 2024, Volume and Issue: unknown, P. 249 - 266

Published: Jan. 1, 2024

Language: Английский

Survey and perspective on verification, validation, and uncertainty quantification of digital twins for precision medicine DOI Creative Commons
Kaan Sel, Andrea Hawkins‐Daarud,

Anirban Chaudhuri

et al.

npj Digital Medicine, Journal Year: 2025, Volume and Issue: 8(1)

Published: Jan. 17, 2025

Digital twins in precision medicine provide tailored health recommendations by simulating patient-specific trajectories and interventions. We examine the critical role of Verification, Validation, Uncertainty Quantification (VVUQ) for digital ensuring safety efficacy, with examples cardiology oncology. highlight challenges opportunities developing personalized trial methodologies, validation metrics, standardizing VVUQ processes. frameworks are essential integrating into clinical practice.

Language: Английский

Citations

5

Integrating large language model and digital twins in the context of industry 5.0: Framework, challenges and opportunities DOI
Chong Chen,

K Zhao,

Jiewu Leng

et al.

Robotics and Computer-Integrated Manufacturing, Journal Year: 2025, Volume and Issue: 94, P. 102982 - 102982

Published: Feb. 10, 2025

Language: Английский

Citations

2

From screens to scenes: A survey of embodied AI in healthcare DOI
Yihao Liu, Xu Cao, Tingting Chen

et al.

Information Fusion, Journal Year: 2025, Volume and Issue: unknown, P. 103033 - 103033

Published: Feb. 1, 2025

Language: Английский

Citations

2

Beyond digital twins: the role of foundation models in enhancing the interpretability of multiomics modalities in precision medicine DOI Creative Commons
Sakhaa B. Alsaedi, Xin Gao, Takashi Gojobori

et al.

FEBS Open Bio, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 24, 2025

Medical digital twins (MDTs) are virtual representations of patients that simulate the biological, physiological, and clinical processes individuals to enable personalized medicine. With increasing complexity omics data, particularly multiomics, there is a growing need for advanced computational frameworks interpret these data effectively. Foundation models (FMs), large‐scale machine learning pretrained on diverse types, have recently emerged as powerful tools improving interpretability decision‐making in precision This review discusses integration FMs into MDT systems, their role enhancing multiomics data. We examine current challenges, recent advancements, future opportunities leveraging analysis MDTs, with focus application

Language: Английский

Citations

1

A comprehensive survey of large language models and multimodal large language models in medicine DOI
Hanguang Xiao,

Feizhong Zhou,

Xingyue Liu

et al.

Information Fusion, Journal Year: 2024, Volume and Issue: unknown, P. 102888 - 102888

Published: Dec. 1, 2024

Language: Английский

Citations

6

Medical Digital Twins for Personalized Chronic Care DOI Creative Commons
M. Papazoglou, Bernd Krämer,

Mira Raheem

et al.

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 16, 2025

Abstract This work introduces the concept of Patient Medical Digital Twins (PMDTs) to simulate treatment outcomes, optimize drug dosages, and deliver personalized chronic care. The PMDT model, supported by an interconnected ecosystem, is validated iteratively medical institutions ensure its efficacy applicability. At core, leverages expressive knowledge structures capture a patient’s psychosomatic, cognitive, biometric, genetic data, creating comprehensive personal digital footprint. enables professionals run simulations predicting health issues over time proactively implement preventive interventions. ecosystem integrates big data analytics, continuous monitoring, cognitive simulation, AI technologies. By connecting stakeholders across care continuum, it provides deeper insights into history supports informed, shared decision-making. Validated in pilot study through EU-funded healthcare initiative, demonstrates transformative potential at intersection Big Data AI, positioning itself as critical tool for advancing

Language: Английский

Citations

0

A Scoping Review of Artificial Intelligence Applications in Clinical Trial Risk Assessment DOI Creative Commons
Douglas Teodoro, Nona Naderi, Anthony Yazdani

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 22, 2025

Abstract Artificial intelligence (AI) is increasingly applied to clinical trial risk assessment, aiming improve safety and efficiency. This scoping review analyzes 142 studies published between 2013 2024, focusing on (n=55), efficacy (n=46), operational (n=45) prediction. AI techniques, including traditional machine learning, deep learning (e.g., graph neural networks, transformers), causal are used for tasks like adverse drug event prediction, treatment effect estimation, phase transition These methods utilize diverse data sources, from molecular structures protocols patient scientific publications. Recently, large language models (LLMs) have seen a surge in applications, representing over 20% of 2023. While some achieve high performance (AUROC up 96%), challenges remain, selection bias, limited prospective studies, quality issues. Despite these limitations, AI-based assessment holds substantial promise transforming trials, particularly through improved risk-based monitoring frameworks.

Language: Английский

Citations

0

The comprehensive clinical benefits of digital phenotyping: from broad adoption to full impact DOI Creative Commons

Yingbo Zhang,

Jiao Wang, Hui Zong

et al.

npj Digital Medicine, Journal Year: 2025, Volume and Issue: 8(1)

Published: April 8, 2025

Digital phenotyping collects health data digitally, supporting early disease diagnosis and management. This paper systematically reviews the diversity of research methods in digital its clinical benefits, while also focusing on importance within P4 medicine paradigm core role advancing application biobanks. Furthermore, envisions continued benefits phenotyping, driven by technological innovation, global collaboration, policy support.

Language: Английский

Citations

0

Clinical Laboratory Parameter–Driven Machine Learning for Participant Selection in Bioequivalence Studies Among Patients With Gastric Cancer: Framework Development and Validation Study DOI Creative Commons
Byungeun Shon,

Sook Jin Seong,

Eun Jung Choi

et al.

JMIR AI, Journal Year: 2025, Volume and Issue: 4, P. e64845 - e64845

Published: May 5, 2025

Abstract Background Insufficient participant enrollment is a major factor responsible for clinical trial failure. Objective We formulated machine learning (ML)–based framework using laboratory parameters to identify participants eligible in bioequivalence study. Methods acquired records of 11,592 patients with gastric cancer from the electronic medical Kyungpook National University Hospital Korea. The ML model was developed 8 parameters, including complete blood count and liver kidney function tests, along dates acquisition. Two datasets were collected: (1) training dataset design an ML-based candidate selection method (2) test evaluate performance proposed method. generalization confirmed F 1 - score area under curve (AUC). compared random its efficacy recruiting participants. Results weighted ensemble achieved strong -score above 0.8 AUC value exceeding 0.8, demonstrating ability accurately valid candidates while minimizing misclassification. Its high sensitivity further enhanced model’s efficiency prioritizing screening. In case study, reduced workload by 57%, efficiently identifying 150 pool 209, 485 required selection. Conclusions can be used trial, enabling faster enrollment.

Language: Английский

Citations

0

Digital twins, synthetic patient data, and in-silico trials: can they empower paediatric clinical trials? DOI Creative Commons
Mohan Pammi, Prakesh S. Shah, Yang Liu

et al.

The Lancet Digital Health, Journal Year: 2025, Volume and Issue: unknown, P. 100851 - 100851

Published: May 1, 2025

Randomised controlled trials are the gold standard to assess effectiveness and safety of clinical interventions; however, many paediatric discontinued early due challenges in patient enrolment. Hence, most suffer from lack adequate power. Additionally, expensive might expose patients unproven therapies. Alternatives overcome these issues using virtual data-namely, digital twins, synthetic data, in-silico trials-are now possible rapid advances health-care tools interventions. However, such innovations have been rarely used trials. In this Viewpoint, we propose data empower The use has advantages decreased exposure children potentially ineffective or risky interventions, shorter trial durations leading more ascertainment faster drug approvals. Use could lead personalised treatment options with low costs result implementation interventions children. ethical regulatory concerns, including replacing humans privacy, security should be addressed sustainability innovation ensured before adopted widely.

Language: Английский

Citations

0